Related Experiment Videos
Beyond a decade of 5% imiquimod topical therapy
Anthony A Gaspari1, Stephen K Tyring, Theodore Rosen
1Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. agasp001@umaryland.edu
Abstract:
The therapeutic potential of imiquimod, a toll-like receptor (TLR)-7 agonist, was recognized in the clinical setting more than a decade ago. Beginning with an approved indication for the treatment of external genital warts in 1997, imiquimod 5% topical cream (Aldara) has received further approval for treating actinic keratosis and superficial basal cell carcinoma. Currently, imiquimod 5% topical cream is the most widely studied and characterized TLR agonist available in the clinical milieu. With new formulations and adjunctive regimens being studied, this paper briefly reviews the mechanisms of action, approved indications, exploratory indications and the role of combination therapy, add-on molecules, and new formulations to overcome treatment limitations.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Clinical Applications of Epidermal Stem Cells
Renewal of Skin Epidermal Stem Cells
Tumor Immunotherapy